Mark Robert Abbruzzese

Mark Abbruzzese practices at Medstar Georgetown Medical Center in Washington, District of Columbia.

Mark Abbruzzese's NPI, 1154310035, was assigned on October 13, 2005. Mark Abbruzzese holds District of Columbia license MD15748.

Mark Abbruzzese's primary practice is Medstar Georgetown Medical Center, at 3800 Reservoir NW Rd, Washington, DC 20007 in District Of Columbia County. The practice phone is (202) 444-1400.

Mark Abbruzzese's primary practice is Medstar Georgetown Medical Center in Washington, District of Columbia. Mark Abbruzzese is also affiliated with MedStar Washington Hospital Center. The medical group on file is MedStar Medical Group. Dmand AI also links Mark Abbruzzese to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mark Abbruzzese practices, 4 sites in all. Vendor and product names are available with a free account.

Infectious disease is Mark Abbruzzese's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dmand AI has Mark Abbruzzese's licenses on file in 2 states: District of Columbia and Maryland.

CMS data shows 1,638 Medicare services from Mark Abbruzzese across 4 procedure codes in 2024, for 237 Medicare patients. Medicare paid $189,827 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 237 Medicare patients who saw Mark Abbruzzese in 2024. The largest group is 65 to 74, with 76 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 3.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Mark Abbruzzese's median patient age at 61, with 43% women.

In 2024, Mark Abbruzzese wrote 236 Medicare Part D claims for 41 patients. 87% of them were for generic drugs. CMS names the drug for 101 of them, across 6 drugs with 11 or more claims each, at $66,005 in total drug cost. In 2023, CMS named 122 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Mark Abbruzzese for performance year 2024, reported as part of a group. Mark Abbruzzese accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 5 general payments to Mark Abbruzzese from 3 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $70.